Pasar al contenido principal

PAPEL DE LA SEÑALIZACION LIPIDICA MEDIADA POR MONOACILGLICEROLES Y ACIDO LISOFOSFATIDICO EN LA ASOCIACION ENTRE TRASTORNOS POR USO DE ALCOHOL Y DEPRESION: IDENTIFICACION DE BIOMARCADORES

PI20/01399

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD (FIMABIS)
Centro realización INSTITUTO DE INVESTIGACION BIOMEDICA DE MALAGA (IBIMA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dysregulation of Plasma Growth Factors and Chemokines in Cocaine Use Disorder, Implications for Dual Diagnosis with Schizophrenia and Antisocial Personality Disorder in an Exploratory Study

  • Torres-Galván, Sandra
  • Flores-López, María|||0000-0003-3489-1465
  • Ochoa, Enrique
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Araos, Pedro|||0000-0001-5172-8796
  • Herrera-Imbroda, Jesús
  • Muga, Roberto|||0000-0001-6301-431X
  • Serrano, Antonia
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
  • Haro, Gonzalo
  • García Marchena, Nuria|||0000-0002-0575-3613
Dual diagnosis in individuals with cocaine use disorders (CUDs) presents a mental health challenge marked by an increased susceptibility to disabling morbidities and premature mortality. Despite extensive research on depression and anxiety, other prevalent comorbidities, such as psychotic and personality disorders, have received less attention. This study explores inflammation-related mediators as potential biomarkers for CUD and dual diagnosis with schizophrenia (SCZ) or antisocial personality disorder (APD). This exploratory study included 95 participants, comprising 40 healthy subjects and 55 abstinent patients with CUD. Lifetime CUD was diagnosed either as single diagnosis (CUD group, N = 25) or as a dual diagnosis (DD group. N = 30) with SCZ (CUD+SCZ subgroup) or APD (CUD+APD subgroup). Participants were clinically assessed, and the plasma concentrations of growth factors (i.e., G-CSF, BDNF, and VEGF-A) and chemokines (i.e., CCL11/eotaxin-1, CCL2/MCP-1, and CXCL12/SDF-1) were determined and log(10)-transformed for analysis. Growth factors and chemokines were dysregulated by CUD and psychiatric diagnoses. Specifically, patients in the CUD group exhibited significantly lower concentrations of G-CSF and CCL11/eotaxin-1 than the control group. In contrast, the DD group showed significantly higher concentrations of all analytes than both the CUD and control groups. Additionally, no differences in these analytes were observed between the CUD+SCZ and CUD+APD subgroups within the DD group. Regarding cocaine-related variables, significant associations were identified in the CUD group: an inverse correlation between the age at first cocaine use and the concentrations of BDNF and CCL2/MCP-1; and a positive correlation between the duration of the cocaine abstinence and the concentrations of BDNF and CCL11/eotaxin-1. Lastly, a logistic regression model incorporating all these analytes demonstrated high discriminatory power in distinguishing patients with CUD alone from those with dual diagnosis. Individuals with dual diagnosis of CUD exhibit elevated concentrations of growth factors and chemokines, distinguishing them from those with CUD alone. It is unclear whether the differences in these inflammatory mediators are specific to the presence of SCZ and APD. The study highlights potential biomarkers and associations, providing valuable insights into the intricate interplay of CUD and psychiatric disorders to enhance clinical diagnosis and therapeutics.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations

  • Padilla, Ana Lizeth
  • Lanciego, José Luis
  • Vila, Miquel
  • Castro Soubriet, Fernando de
  • Pozo, David
  • Rodríguez de Fonseca, Fernando
  • Serrano, Antonia
  • Sáez-Valero, Javier
  • Núñez, Lucía
  • Villalobos, Carlos
  • Tapias, Víctor
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons and the pathological aggregation of α-synuclein. While current pharmacological therapies provide symptomatic relief, they do not halt or reverse disease progression. Cell-based regenerative strategies have emerged as promising approaches to restore DA function and target the complex, multifactorial pathophysiology of PD. This review critically examines current approaches, including transplantation of fetal ventral mesencephalic tissue, pluripotent stem cell-derived midbrain DA progenitors, and in vivo reprogramming of endogenous cells. In addition, supportive cell types, such as mesenchymal stromal cells and carotid body glomus cells, provide neuroprotective and immunomodulatory effects via paracrine signaling. We summarize preclinical and clinical evidence on graft survival, integration, and functional recovery, and discuss key determinants of therapeutic efficacy, including mitochondrial function and bioenergetic integrity, immune compatibility, and biomaterial scaffolding. Despite significant progress, major challenges remain regarding long-term efficacy, graft standardization, and host-graft interactions. Ongoing translational advances are poised to drive the development of disease-modifying cell therapies capable of delivering durable clinical benefits and improving long-term outcomes in PD., This work was supported by the Aligning Science Across Parkinson's (#ASAP-020505, USA) through the Michael J. Fox Foundation for Parkinson's Research (MJFF), Ministerio de Ciencia, Innovación y Universidades y Agencia Estatal de Investigación (MICIN/AEI, #PID2020-120308RB, Spain), CiberNed Intramural Collaborative Projects (#PI2020/09, Spain) and Fundación Mutua Madrileña de Investigación Médica (#FMM2020, Spain) to José L. Lanciego; Aligning Science Across Parkinson's (#ASAP-020505, USA) through the MJFF (USA), MICIN/AEI (#PID2020-116339RB-I00, Spain) to Miquel Vila; MICIN/AEI (#PID2022-143110OB-100, Spain), Fundación Ramón Areces (#CIVP19A5917, Spain), Fundación Merck Salud (2023, Spain) and Fundación Grupo de Afectados por Esclerosis Multiple (GAEM, #050601240006, Spain) in collaboration with research networks #RED2022-134081-T and #RED2022-134425-T to Fernando de Castro; MICIN/AEI (#PI22/00427 and #PI20/01399, Spain) and European Regional Development Funds-European Union (ERDF-EU) to Fernando Rodríguez de Fonseca and Antonia Serrano; MICIN/AEI (#RTI2018-098432-BI00), Junta de Andalucía (#PI-232-2022 and #CTS-677), Fundació Catalana d’ELA Miquel Valls (2022, Spain), Fundación Juntos contra la ELA (2023, Spain) to David Pozo; Fondo de Investigaciones Sanitarias (#PI22/01329, Spain), Fondo Europeo de Desarrollo Regional (FEDER), and Dirección General de Ciencia e Investigación de la Generalitat Valenciana (CIAICO/2024/313, Spain) to Javier Sáez-Valero; Excellence Program from Junta de Castilla y León (#CCVC8485, Spain) and MICIN/AEI (#PID2021-125909OB-100, Spain) to Carlos Villalobos and Lucía Núñez, and Junta de Castilla y León (#VA294P18, Spain) to Lucía Núñez; María Zambrano's Excellence Program from the MICIN/AEI (#CONVREC-2021-278, Spain), University of Valladolid and the Internationalization program of Junta de Castilla y León (#CL-EI-2021-09, Spain) to Victor Tapias., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Flores-López, María|||0000-0003-3489-1465
  • Papaseit, Esther|||0000-0003-2620-4274
  • García Marchena, Nuria|||0000-0002-0575-3613
  • Ruiz, Juan Jesús
  • Ortega-Pinazo, Jesús
  • Serrano, Antonia
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Suarez, Juan|||0000-0001-5254-9802
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Araos, Pedro|||0000-0001-5172-8796
(1) Background: Alcohol Use Disorder (AUD) is associated with functional disruption of several brain structures that may trigger cognitive dysfunction. One of the mechanisms of alcohol-associated cognitive impairment has been proposed to arise from its direct impact on the immune system, which culminates in the release of cytokines and chemokines which can eventually reach the brain. Alcohol can also disrupt the blood-brain barrier, facilitating the penetration of pro-inflammatory molecules throughout vascular endothelial growth factor A (VEGFA). Thus, alcohol-induced alterations in chemokines and VEGFA might contribute to the neuroinflammation and cognitive impairment associated with AUD. (2) Methods: The present cross-sectional study investigates whether patients with AUD (n = 86) present cognitive disability associated to alterations in plasma concentration of SDF-1, fractalkine, eotaxin, MCP-1, MIP-1α and VEGFA when compared to control subjects (n = 51). (3) Results: The analysis indicated that SDF-1 and MCP-1 concentrations were higher in AUD patients than in controls. Concentrations of VEGFA were higher in AUD patients with severe frontal deficits, and the score of frontal lobe functions was negatively correlated with VEGFA and fractalkine. Acute alcohol effects on VEGFA plasma levels in healthy volunteers demonstrated the induction of VEGFA release by heavy alcohol drinking. VEGFA was positively correlated with pro-inflammatory chemokines in AUD patients with frontal cognitive impairment. (4) Conclusions: we propose VEGFA/chemokine monitoring as biomarkers of potential cognitive impairment in AUD patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex

  • García Marchena, Nuria|||0000-0002-0575-3613
  • Marcos, Alberto
  • Flores-López, María|||0000-0003-3489-1465
  • Moreno-Fernández, Mario
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Porras-Perales, Oscar
  • Torres-Galván, Sandra
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Muga, Roberto|||0000-0001-6301-431X
  • Ruiz-Ruiz, Juan Jesús|||0000-0001-8692-4463
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Ambrosio, Emilio
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
(1) Background: Co-occurrence of mental and substance use disorders (SUD) is prevalent, but complicates their clinical courses, and specific biomarkers are required. Amino acids are altered in primary mental disorders; however, little is known about SUD and psychiatric comorbidity. Because most psychiatric disorders and biomarkers show sex differences, we investigated amino acids in men and women with alcohol and/or cocaine use disorders (AUD and/or CUD) and psychiatric comorbidity. (2) Methods: A cross-sectional study was conducted in 295 participants, who were divided into four groups (AUD, n = 60; CUD, n = 41; AUD + CUD, n = 64; and control, n = 130). Participants were clinically assessed, and plasma amino acid concentrations were analyzed in relation to sex, diagnosis of SUD and psychiatric comorbidity (3) Results: In the total sample, there were sex differences, and women showed lower Iso, Leu, Gln and Glu than men. While patients with CUD and AUD + CUD had higher Glu, Gly, Orn and Ser than controls, patients with AUD showed no differences. In SUD, patients with psychiatric comorbidity had lower Orn and higher Ala than non-comorbid patients in the AUD group. (4) Conclusions: There was a dysregulation of plasma amino acids in abstinent patients with SUD. However, our results suggest the importance of considering the clinical characteristics and sex in the validity of amino acids as potential biomarkers for SUD.